Identification

Name
Diclofenac
Accession Number
DB00586  (APRD00527)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]

Structure
Thumb
Synonyms
  • [2-(2,6-dichloroanilino)phenyl]acetic acid
  • 2-((2,6-dichlorophenyl)amino)benzeneacetic acid
  • Diclofenac Acid
  • Diclofenaco
  • Diclofenacum
External IDs
ISV-205
Product Ingredients
IngredientUNIICASInChI Key
Diclofenac diethylamine6TGQ35Z71K78213-16-8ZQVZPANTCLRASL-UHFFFAOYSA-N
Diclofenac epolamineX5F8EKL9ZG119623-66-4DCERVXIINVUMKU-UHFFFAOYSA-N
Diclofenac potassiumL4D5UA6CB415307-81-0KXZOIWWTXOCYKR-UHFFFAOYSA-M
Diclofenac sodiumQTG126297Q15307-79-6KPHWPUGNDIVLNH-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-diclofenacTablet, delayed release50 mgOralAvanstra Inc2011-08-182014-08-21Canada
Ava-diclofenacTablet, delayed release25 mgOralAvanstra Inc2011-08-182014-08-21Canada
Ava-diclofenac SRTablet, extended release75 mgOralAvanstra Inc2011-08-182014-08-21Canada
Ava-diclofenac SRTablet, extended release100 mgOralAvanstra Inc2011-09-272014-08-21Canada
CambiaPowder, for solution50 mg/1OralDepomed2010-04-20Not applicableUs
CambiaPowder, for solution50 mgOralTribute Pharmaceuticals2012-06-02Not applicableCanada
CambiaPowder, for solution1 mg/mgOralNautilus Neurosciences, Inc.2010-04-20Not applicableUs
CambiaPowder, for solution50 mg/1OralDepomed2016-03-10Not applicableUs
CataflamTablet, sugar coated50 mg/1OralNovartis1993-11-242017-01-01Us
Diclo Gel 1% with Xrylix SheetsKitShoreline Pharmaceuticals, Inc.2016-09-22Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-dicloTablet, delayed release25 mgOralApotex Corporation1989-12-31Not applicableCanada
Apo-dicloTablet, delayed release50 mgOralApotex Corporation1989-12-31Not applicableCanada
Apo-diclo Rapide 50 Mg TabletsTablet50 mgOralApotex Corporation2001-05-25Not applicableCanada
Apo-diclo SRTablet, extended release75 mgOralApotex Corporation1995-12-31Not applicableCanada
Apo-diclo SRTablet, extended release100 mgOralApotex Corporation1994-12-31Not applicableCanada
Apo-diclofenacSolution1.5 %TopicalApotex CorporationNot applicableNot applicableCanada
Apo-diclofenac OphthalmicSolution0.1 %OphthalmicApotex Corporation2015-09-01Not applicableCanada
DiclofenacSolution / drops1 mg/mLOphthalmicA S Medication Solutions2008-05-012017-06-20Us
DiclofenacSolution / drops1 mg/mLOphthalmicLake Erie Medical Dba Quality Care Produts Llc2008-05-01Not applicableUs
DiclofenacSolution / drops1 mg/mLOphthalmicAltaire Pharmaceuticals Inc.2015-11-16Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Voltaren EmulgelGel1.16 %TopicalGlaxosmithkline Inc2008-09-02Not applicableCanada
Voltaren Emulgel Back & Muscle PainGel1.16 %TopicalGlaxosmithkline IncNot applicableNot applicableCanada
Voltaren Emulgel Extra StrengthGel2.32 %TopicalGlaxosmithkline Inc2014-10-06Not applicableCanada
Voltaren Emulgel Joint Pain Extra StrengthGel2.32 %TopicalGlaxosmithkline IncNot applicableNot applicableCanada
Voltaren Emulgel Joint Pain Regular StrengthGel1.16 %TopicalGlaxosmithkline Inc2010-06-21Not applicableCanada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Diclofenac SodiumAerosol, metered30 mg/mLTopicalShoreline Pharmaceuticals, Inc.2016-01-07Not applicableUs
Diclofenac SodiumTablet, film coated, extended release100 mg/1OralNu Care Pharmaceuticals,inc.2000-02-28Not applicableUs
Diclofenac SodiumSolution16.05 mg/mLTopicalRemedy Repack2017-11-27Not applicableUs
Diclofenac SodiumGel3 g/100gTopicalTwo Hip Consulting, Llc2016-03-25Not applicableUs
Diclofenac SodiumGel30 mg/gTopicalRemedy Repack2017-11-15Not applicableUs
Diclofenac SodiumSolution16.05 mg/mLTopicalDirectrx2017-10-31Not applicableUs
Diclofenac Sodium 1.5%Solution16.05 mg/mLTopicalKbs Solutions Llc2017-11-20Not applicableUs
Diclofenac Sodium 3 PercentCream300 mg/gTopicalHumco Holding Group. Inc.2016-06-01Not applicableUs
Diclofenac Sodium Delayed ReleaseTablet, delayed release75 mg/1OralSt. Mary's Medical Park Pharnacy1998-11-13Not applicableUs
Diclofenac Sodium Topical SolutionSolution16.05 mg/mLTopicalIngenus Pharmaceuticals Llc2017-11-01Not applicableUs
International/Other Brands
Aclonac / Allvoran / Ecofenac / Effekton / Nu-Diclo / Primofenac / Prophenatin / Rhumalgan / Voltaren Emulgel / Voltarol
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Act Diclo-misoDiclofenac sodium (50 mg) + Misoprostol (200 mcg)Tablet, delayed releaseOralActavis Pharma Company2013-03-27Not applicableCanada
Act Diclo-misoDiclofenac sodium (75 mg) + Misoprostol (200 mcg)Tablet, delayed releaseOralActavis Pharma Company2013-03-27Not applicableCanada
ArthrotecDiclofenac sodium (75 mg/1) + Misoprostol (200 ug/1)Tablet, film coatedOralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-02-23Not applicableUs
ArthrotecDiclofenac sodium (75 mg/1) + Misoprostol (200 ug/1)Tablet, film coatedOralA S Medication Solutions1997-12-242017-06-20Us
ArthrotecDiclofenac sodium (50 mg/1) + Misoprostol (200 ug/1)Tablet, film coatedOralG.D. Searle LLC Division of Pfizer Inc1997-12-24Not applicableUs00025 1411 60 nlmimage10 c812e407
ArthrotecDiclofenac sodium (75 mg/1) + Misoprostol (200 ug/1)Tablet, film coatedOralRebel Distributors1997-12-24Not applicableUs
ArthrotecDiclofenac sodium (75 mg/1) + Misoprostol (200 ug/1)Tablet, film coatedOralPhysicians Total Care, Inc.2004-12-28Not applicableUs
ArthrotecDiclofenac sodium (75 mg/1) + Misoprostol (200 ug/1)Tablet, film coatedOralStat Rx USA1997-12-24Not applicableUs
ArthrotecDiclofenac sodium (50 mg/1) + Misoprostol (200 ug/1)Tablet, film coatedOralPd Rx Pharmaceuticals, Inc.1997-12-24Not applicableUs
ArthrotecDiclofenac sodium (50 mg/1) + Misoprostol (200 ug/1)Tablet, film coatedOralPhysicians Total Care, Inc.2009-10-07Not applicableUs
Categories
UNII
144O8QL0L1
CAS number
15307-86-5
Weight
Average: 296.149
Monoisotopic: 295.016684015
Chemical Formula
C14H11Cl2NO2
InChI Key
DCOPUUMXTXDBNB-UHFFFAOYSA-N
InChI
InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)
IUPAC Name
2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid
SMILES
OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl

Pharmacology

Indication

For the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.

Structured Indications
Pharmacodynamics

Diclofenac is an acetic acid nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties. Diclofenac is used to treat pain, dysmenorrhea, ocular inflammation, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and actinic keratosis

Mechanism of action

The antiinflammatory effects of diclofenac are believed to be due to inhibition of both leukocyte migration and the enzyme cylooxygenase (COX-1 and COX-2), leading to the peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, inhibition of their synthesis is responsible for the analgesic effects of diclofenac. Antipyretic effects may be due to action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat dissipation.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
AProstaglandin G/H synthase 1
inhibitor
Human
AArachidonate 5-lipoxygenase
potentiator
Human
ASodium channel protein type 4 subunit alpha
inhibitor
Human
AAcid-sensing ion channel 1
inhibitor
Human
APotassium voltage-gated channel subfamily KQT member 2
other
Human
APotassium voltage-gated channel subfamily KQT member 3
other
Human
UPhospholipase A2, membrane associated
inhibitor
Human
Absorption

Completely absorbed from the gastrointestinal tract.

Volume of distribution
  • 1.3 L/kg
Protein binding

More than 99%

Metabolism

Hepatic

Route of elimination

Diclofenac is eliminated through metabolism and subsequent urinary and biliary excretion of the glucuronide and the sulfate conjugates of the metabolites. Little or no free unchanged diclofenac is excreted in the urine. Approximately 65% of the dose is excreted in the urine and approximately 35% in the bile as conjugates of unchanged diclofenac plus metabolites.

Half life

2 hours

Clearance
  • oral cl=622 mL/min [healthy]
  • renal cl <1 mL/min [healthy]
Toxicity

Symptoms of overdose include loss of consciousness, increased intracranial pressure, and aspiration pneumonitis. LD50=390mg/kg (orally in mice)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Diclofenac Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Diclofenac is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Diclofenac is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Diclofenac is combined with 5-androstenedione.Experimental, Illicit
AbciximabDiclofenac may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Diclofenac can be increased when it is combined with Abiraterone.Approved
AcebutololDiclofenac may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Diclofenac is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolDiclofenac may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Diclofenac is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinDiclofenac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Diclofenac.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Diclofenac is combined with Alendronic acid.Approved
AliskirenDiclofenac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Alminoprofen.Experimental
AlprenololDiclofenac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Diclofenac.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Amcinonide.Approved
AmikacinDiclofenac may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideDiclofenac may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe serum concentration of Diclofenac can be increased when it is combined with Amiodarone.Approved, Investigational
AmrubicinDiclofenac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodDiclofenac may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Diclofenac is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Diclofenac is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Anisodamine.Investigational
annamycinDiclofenac may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Antipyrine.Approved
Antithrombin III humanDiclofenac may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanDiclofenac may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Diclofenac is combined with Apocynin.Investigational
ApramycinDiclofenac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Diclofenac is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Diclofenac can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinDiclofenac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinDiclofenac may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanDiclofenac may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArmodafinilThe metabolism of Diclofenac can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololDiclofenac may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Atamestane.Investigational
AtazanavirThe metabolism of Diclofenac can be decreased when combined with Atazanavir.Approved, Investigational
AtenololDiclofenac may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Diclofenac can be decreased when combined with Atomoxetine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Diclofenac.Approved
AzithromycinThe metabolism of Diclofenac can be decreased when combined with Azithromycin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Balsalazide.Approved, Investigational
BecaplerminDiclofenac may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololDiclofenac may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinDiclofenac may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Diclofenac.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Diclofenac.Approved
BenorilateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Diclofenac.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Betamethasone.Approved, Vet Approved
BetaxololDiclofenac may decrease the antihypertensive activities of Betaxolol.Approved
BevantololDiclofenac may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Diclofenac is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Diclofenac.Approved, Investigational
BisoprololDiclofenac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinDiclofenac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Diclofenac can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololDiclofenac may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Diclofenac can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Diclofenac can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Diclofenac.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Diclofenac.Approved
BromfenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Bucillamine.Investigational
BucindololDiclofenac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Bufexamac.Experimental
BufuralolDiclofenac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Bumadizone.Experimental
BumetanideDiclofenac may decrease the diuretic activities of Bumetanide.Approved
BupranololDiclofenac may decrease the antihypertensive activities of Bupranolol.Approved
CaffeineThe metabolism of Diclofenac can be decreased when combined with Caffeine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Diclofenac.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Diclofenac.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Diclofenac.Experimental
CapecitabineThe serum concentration of Diclofenac can be increased when it is combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Diclofenac.Approved
CarbamazepineThe serum concentration of Diclofenac can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Diclofenac.Approved
CarprofenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololDiclofenac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolDiclofenac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Diclofenac is combined with Celecoxib.Approved, Investigational
CeliprololDiclofenac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Diclofenac can be increased when it is combined with Ceritinib.Approved
CertoparinDiclofenac may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloramphenicolThe metabolism of Diclofenac can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Diclofenac.Approved
CholecalciferolThe metabolism of Diclofenac can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Diclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Diclofenac.Approved
CimetidineThe metabolism of Diclofenac can be decreased when combined with Cimetidine.Approved
CinoxacinDiclofenac may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Diclofenac can be decreased when combined with Citalopram.Approved
Citric AcidDiclofenac may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Diclofenac can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Diclofenac can be decreased when combined with Clemastine.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Diclofenac is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Diclofenac is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Diclofenac is combined with Clonixin.Approved
ClopidogrelThe metabolism of Diclofenac can be decreased when combined with Clopidogrel.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Diclofenac.Vet Approved
CloranololDiclofenac may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Diclofenac can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Diclofenac can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Diclofenac.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Diclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Diclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Diclofenac can be increased when it is combined with Conivaptan.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Cortisone acetate.Approved
CrisaboroleThe metabolism of Diclofenac can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Diclofenac can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Diclofenac is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Diclofenac.Experimental
CyclosporineDiclofenac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Diclofenac can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when Diclofenac is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Diclofenac.Approved
DabrafenibThe serum concentration of Diclofenac can be decreased when it is combined with Dabrafenib.Approved
DalteparinDiclofenac may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidDiclofenac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanDiclofenac may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe metabolism of Diclofenac can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Diclofenac can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinDiclofenac may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Diclofenac can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Diclofenac is combined with Deflazacort.Approved
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Diclofenac.Experimental
DelavirdineThe serum concentration of Diclofenac can be increased when it is combined with Delavirdine.Approved
DesipramineThe metabolism of Diclofenac can be decreased when combined with Desipramine.Approved
DesirudinDiclofenac may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Diclofenac is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Diclofenac.Approved, Investigational
DextranDiclofenac may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Diclofenac may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Diclofenac may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Diclofenac may increase the anticoagulant activities of Dextran 75.Approved
DibekacinDiclofenac may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DicoumarolDiclofenac may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diclofenac is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Diclofenac.Approved
DihydroergotamineThe metabolism of Diclofenac can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinDiclofenac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe metabolism of Diclofenac can be decreased when combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Diclofenac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Diclofenac.Approved
DosulepinThe serum concentration of Diclofenac can be increased when it is combined with Dosulepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Diclofenac.Approved, Investigational
DoxorubicinDiclofenac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Diclofenac can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Diclofenac can be decreased when combined with Dronedarone.Approved
DrospirenoneDiclofenac may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Diclofenac is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Diclofenac is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Diclofenac is combined with E-6201.Investigational
Edetic AcidDiclofenac may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Diclofenac.Approved
EfavirenzThe metabolism of Diclofenac can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Diclofenac.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Diclofenac.Approved
EnoxacinDiclofenac may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinDiclofenac may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Diclofenac.Experimental
EnzalutamideThe serum concentration of Diclofenac can be decreased when it is combined with Enzalutamide.Approved
EpanololDiclofenac may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Diclofenac is combined with Epirizole.Approved
EpirubicinDiclofenac may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneDiclofenac may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Diclofenac.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Diclofenac.Approved
EquileninThe risk or severity of adverse effects can be increased when Diclofenac is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Diclofenac is combined with Equilin.Approved
ErythromycinThe metabolism of Diclofenac can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe metabolism of Diclofenac can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololDiclofenac may decrease the antihypertensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Diclofenac can be decreased when combined with Esomeprazole.Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Estrone sulfate.Approved
Etacrynic acidDiclofenac may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Diclofenac is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ethenzamide.Experimental
Ethyl biscoumacetateDiclofenac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Diclofenac is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Diclofenac is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Diclofenac can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Diclofenac is combined with Evening primrose oil.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Diclofenac.Approved
exisulindThe risk or severity of adverse effects can be increased when Diclofenac is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Felbinac.Experimental
FelodipineThe metabolism of Diclofenac can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Diclofenac.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Feprazone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Diclofenac.Approved, Investigational
FleroxacinDiclofenac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe serum concentration of Diclofenac can be increased when it is combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Diclofenac is combined with fluasterone.Investigational
FluconazoleThe serum concentration of Diclofenac can be increased when it is combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fludrocortisone.Approved
FluindioneDiclofenac may increase the anticoagulant activities of Fluindione.Investigational
FlumequineDiclofenac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Diclofenac is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fluorometholone.Approved
FluorouracilThe serum concentration of Diclofenac can be increased when it is combined with Fluorouracil.Approved
FluoxetineThe metabolism of Diclofenac can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Diclofenac.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Diclofenac can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Diclofenac can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Diclofenac.Approved, Nutraceutical, Vet Approved
FondaparinuxDiclofenac may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumDiclofenac may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Diclofenac.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Diclofenac can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Diclofenac can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Diclofenac.Approved
FosphenytoinThe serum concentration of Diclofenac can be decreased when it is combined with Fosphenytoin.Approved
FramycetinDiclofenac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideDiclofenac may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Diclofenac can be increased when it is combined with Fusidic Acid.Approved
GabexateDiclofenac may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinDiclofenac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinDiclofenac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Diclofenac.Approved, Withdrawn
GemfibrozilThe serum concentration of Diclofenac can be increased when it is combined with Gemfibrozil.Approved
GemifloxacinDiclofenac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinDiclofenac may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinDiclofenac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ADiclofenac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Diclofenac may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinDiclofenac may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Diclofenac is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Diclofenac is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Diclofenac is combined with HE3286.Investigational
HeparinDiclofenac may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Higenamine.Investigational
HydralazineDiclofenac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Diclofenac.Approved, Investigational
Hygromycin BDiclofenac may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Diclofenac is combined with Icatibant.Approved
IdarubicinDiclofenac may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxDiclofenac may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Diclofenac.Approved, Investigational
ImatinibThe metabolism of Diclofenac can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Diclofenac.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Diclofenac.Approved
IndenololDiclofenac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Diclofenac can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Diclofenac is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Indoprofen.Withdrawn
INNO-206Diclofenac may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Diclofenac can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Diclofenac can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinDiclofenac may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoniazidThe metabolism of Diclofenac can be decreased when combined with Isoniazid.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Diclofenac is combined with Isoxicam.Withdrawn
IsradipineThe metabolism of Diclofenac can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Diclofenac is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Diclofenac can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Diclofenac can be increased when it is combined with Ivacaftor.Approved
KanamycinDiclofenac may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Diclofenac can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ketorolac.Approved
LabetalolDiclofenac may decrease the antihypertensive activities of Labetalol.Approved
LandiololDiclofenac may decrease the antihypertensive activities of Landiolol.Investigational
LapatinibThe metabolism of Diclofenac can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Diclofenac.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Diclofenac.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Diclofenac.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Leflunomide.Approved, Investigational
LepirudinDiclofenac may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanDiclofenac may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololDiclofenac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinDiclofenac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LidocaineThe metabolism of Diclofenac can be decreased when combined with Lidocaine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Diclofenac.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Diclofenac.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Diclofenac.Approved
LobeglitazoneThe metabolism of Diclofenac can be decreased when combined with Lobeglitazone.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Lonazolac.Experimental
LopinavirThe metabolism of Diclofenac can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Diclofenac is combined with Lornoxicam.Approved, Investigational
LosartanThe metabolism of Diclofenac can be decreased when combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Diclofenac is combined with Loteprednol.Approved
LovastatinThe metabolism of Diclofenac can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Diclofenac.Approved, Investigational
LuliconazoleThe serum concentration of Diclofenac can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Diclofenac can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Diclofenac is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Diclofenac.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Magnesium salicylate.Approved
ManidipineThe metabolism of Diclofenac can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Diclofenac is combined with Masoprocol.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Diclofenac is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Diclofenac is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mefenamic acid.Approved
MelagatranDiclofenac may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Diclofenac is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Diclofenac is combined with Meloxicam.Approved, Vet Approved
MepindololDiclofenac may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Diclofenac is combined with Metamizole.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Diclofenac.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diclofenac.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Methylprednisolone.Approved, Vet Approved
MetipranololDiclofenac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Diclofenac.Approved
MetoprololDiclofenac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideDiclofenac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MexiletineThe metabolism of Diclofenac can be decreased when combined with Mexiletine.Approved
MicronomicinDiclofenac may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe serum concentration of Diclofenac can be increased when it is combined with Midostaurin.Approved
MifepristoneThe serum concentration of Diclofenac can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Diclofenac.Approved
MitotaneThe serum concentration of Diclofenac can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Diclofenac can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Diclofenac can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Diclofenac.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Diclofenac.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nabumetone.Approved
NadololDiclofenac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinDiclofenac may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Naftifine.Approved
Nalidixic AcidDiclofenac may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Diclofenac.Approved
NaproxenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Diclofenac is combined with NCX 1022.Investigational
NeamineDiclofenac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololDiclofenac may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Diclofenac can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Diclofenac can be decreased when combined with Nelfinavir.Approved
NemonoxacinDiclofenac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinDiclofenac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nepafenac.Approved
NetilmicinDiclofenac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NetupitantThe serum concentration of Diclofenac can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Diclofenac can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Diclofenac can be increased when it is combined with Nicardipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Diclofenac is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Diclofenac can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nitroaspirin.Investigational
NorfloxacinDiclofenac may increase the neuroexcitatory activities of Norfloxacin.Approved
OlaparibThe metabolism of Diclofenac can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Diclofenac.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Diclofenac.Investigational
OmeprazoleThe metabolism of Diclofenac can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Diclofenac is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Diclofenac can be increased when it is combined with Osimertinib.Approved
OtamixabanDiclofenac may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Diclofenac is combined with Oxaprozin.Approved
Oxolinic acidDiclofenac may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololDiclofenac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Oxyphenbutazone.Approved, Withdrawn
PalbociclibThe serum concentration of Diclofenac can be increased when it is combined with Palbociclib.Approved
PamidronateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pamidronate.Approved
PantoprazoleThe metabolism of Diclofenac can be decreased when combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Diclofenac is combined with Parecoxib.Approved
ParomomycinDiclofenac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineThe metabolism of Diclofenac can be decreased when combined with Paroxetine.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Parthenolide.Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Diclofenac.Approved
PazufloxacinDiclofenac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinDiclofenac may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Diclofenac can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololDiclofenac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateDiclofenac may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalThe metabolism of Diclofenac can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateDiclofenac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Diclofenac.Approved
PhenindioneDiclofenac may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe serum concentration of Diclofenac can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonDiclofenac may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Diclofenac can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pimecrolimus.Approved, Investigational
PindololDiclofenac may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Diclofenac can be decreased when combined with Pioglitazone.Approved, Investigational
Pipemidic acidDiclofenac may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinDiclofenac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideDiclofenac may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pirfenidone.Approved, Investigational
Piromidic acidDiclofenac may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Diclofenac is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pirprofen.Experimental
Platelet Activating FactorDiclofenac may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinDiclofenac may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinDiclofenac may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Diclofenac.Approved
PosaconazoleThe metabolism of Diclofenac can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololDiclofenac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Diclofenac.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pregnenolone.Experimental, Investigational
PrimidoneThe serum concentration of Diclofenac can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Diclofenac can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Diclofenac is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Diclofenac is combined with Propacetamol.Approved, Investigational
PropranololDiclofenac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Diclofenac.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Diclofenac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Diclofenac.Vet Approved
Protein CDiclofenac may increase the anticoagulant activities of Protein C.Approved
Protein S humanDiclofenac may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDiclofenac may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Diclofenac.Approved
PrulifloxacinDiclofenac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Diclofenac is combined with PTC299.Investigational
PuromycinDiclofenac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Diclofenac can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Diclofenac can be increased when it is combined with Quazepam.Approved, Illicit
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Diclofenac.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Diclofenac.Approved
QuinineThe metabolism of Diclofenac can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Diclofenac can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Diclofenac.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Diclofenac.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Diclofenac.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Diclofenac is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinDiclofenac may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinDiclofenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifabutinThe metabolism of Diclofenac can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Diclofenac can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Diclofenac can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Diclofenac.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Risedronate.Approved, Investigational
RivaroxabanDiclofenac may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Diclofenac is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe metabolism of Diclofenac can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Diclofenac can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinDiclofenac may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinDiclofenac may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinDiclofenac may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Diclofenac.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Diclofenac is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Diclofenac.Experimental
SaquinavirThe metabolism of Diclofenac can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Diclofenac.Investigational
SecobarbitalThe serum concentration of Diclofenac can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Diclofenac is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Diclofenac is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Diclofenac is combined with Serrapeptase.Investigational
SertralineThe metabolism of Diclofenac can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Diclofenac can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Diclofenac.Approved
SiltuximabThe serum concentration of Diclofenac can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Diclofenac can be increased when it is combined with Simeprevir.Approved
SisomicinDiclofenac may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinDiclofenac may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Diclofenac.Approved
SorafenibThe metabolism of Diclofenac can be decreased when combined with Sorafenib.Approved, Investigational
SotalolDiclofenac may decrease the antihypertensive activities of Sotalol.Approved
SP1049CDiclofenac may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinDiclofenac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinDiclofenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Diclofenac.Approved
SpironolactoneDiclofenac may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Diclofenac is combined with SRT501.Investigational
St. John's WortThe serum concentration of Diclofenac can be decreased when it is combined with St. John&#39;s Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Diclofenac can be increased when it is combined with Stiripentol.Approved
StreptomycinDiclofenac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinDiclofenac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe serum concentration of Diclofenac can be increased when it is combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Diclofenac can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Sulfasalazine.Approved
SulfisoxazoleThe serum concentration of Diclofenac can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Sulindac.Approved
SulodexideDiclofenac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Diclofenac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Suxibuzone.Experimental
TacrolimusDiclofenac may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Diclofenac.Approved
TalinololDiclofenac may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Diclofenac.Approved
TamoxifenThe metabolism of Diclofenac can be decreased when combined with Tamoxifen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Diclofenac.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Diclofenac is combined with Technetium Tc-99m medronate.Approved
TelaprevirThe metabolism of Diclofenac can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Diclofenac can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Diclofenac.Approved, Investigational
TemafloxacinDiclofenac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Diclofenac.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Teriflunomide.Approved
TertatololDiclofenac may decrease the antihypertensive activities of Tertatolol.Experimental
TheophyllineThe metabolism of Diclofenac can be decreased when combined with Theophylline.Approved
ThiotepaThe metabolism of Diclofenac can be decreased when combined with Thiotepa.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Diclofenac can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Diclofenac can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololDiclofenac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tixocortol.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Diclofenac.Approved
TobramycinDiclofenac may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Diclofenac can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe serum concentration of Diclofenac can be increased when it is combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tolmetin.Approved
TopiramateThe metabolism of Diclofenac can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Diclofenac can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Diclofenac.Approved, Investigational
TorasemideDiclofenac may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Diclofenac.Approved
TranilastThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Diclofenac can be decreased when combined with Tranylcypromine.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Diclofenac.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Diclofenac.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Diclofenac is combined with Triamcinolone.Approved, Vet Approved
TriamtereneDiclofenac may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
TrimethoprimThe metabolism of Diclofenac can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Diclofenac is combined with Triptolide.Investigational
TrovafloxacinDiclofenac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinDiclofenac may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Diclofenac.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Diclofenac is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Diclofenac can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinDiclofenac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Diclofenac can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Diclofenac.Approved
VenlafaxineThe metabolism of Diclofenac can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Diclofenac can be decreased when combined with Verapamil.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Diclofenac.Approved, Investigational
VoriconazoleThe serum concentration of Diclofenac can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinDiclofenac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranDiclofenac may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Diclofenac can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Diclofenac is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Diclofenac is combined with Zileuton.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Diclofenac can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Diclofenac.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Diclofenac is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Diclofenac is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinDiclofenac may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinDiclofenac may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
ZucapsaicinThe metabolism of Diclofenac can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

References

Synthesis Reference

Takuzo Kamishita, "Gel preparations for topical application of diclofenac sodium." U.S. Patent US4670254, issued October, 1983.

US4670254
General References
  1. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006 Jun 3;332(7553):1302-8. [PubMed:16740558]
  2. Solomon DH, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S: Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006 May;54(5):1378-89. [PubMed:16645966]
  3. FitzGerald GA, Patrono C: The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001 Aug 9;345(6):433-42. [PubMed:11496855]
  4. Graham DJ: COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA. 2006 Oct 4;296(13):1653-6. Epub 2006 Sep 12. [PubMed:16968830]
  5. Brater DC: Renal effects of cyclooxygyenase-2-selective inhibitors. J Pain Symptom Manage. 2002 Apr;23(4 Suppl):S15-20; discussion S21-3. [PubMed:11992745]
  6. Gan TJ: Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin. 2010 Jul;26(7):1715-31. doi: 10.1185/03007995.2010.486301. [PubMed:20470236]
  7. Link [Link]
External Links
Human Metabolome Database
HMDB14724
KEGG Drug
D07816
KEGG Compound
C01690
PubChem Compound
3033
PubChem Substance
46504644
ChemSpider
2925
BindingDB
13066
ChEBI
47381
ChEMBL
CHEMBL139
Therapeutic Targets Database
DAP000620
PharmGKB
PA449293
IUPHAR
2714
Guide to Pharmacology
GtP Drug Page
HET
DIF
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Diclofenac
ATC Codes
M01AB05 — DiclofenacS01BC03 — DiclofenacM01AB55 — Diclofenac, combinationsM02AA15 — DiclofenacS01CC01 — Diclofenac and antiinfectivesD11AX18 — Diclofenac
AHFS Codes
  • 28:08.04.08 — Cyclooxygenase-2 (COX-2) Inhibitors
  • 52:08.20 — Nonsteroidal Anti-inflammatory Agents
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
PDB Entries
1dvx / 1nr6 / 1pxx / 1sv9 / 2b17 / 2wek / 3cfq / 3ib0 / 3n8y / 4oj4
show 7 more
FDA label
Download (37.5 KB)
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentCancer, Breast1
0CompletedBasic ScienceBioequivalence1
0Not Yet RecruitingTreatmentOsteoarthritis of the Hands1
0RecruitingDiagnosticRespiratory Insufficiency1
0RecruitingOtherBioavailability1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHealthy Volunteers / Hepatic Insufficiency / Renal Insufficiency,Chronic1
1CompletedNot AvailablePain1
1CompletedNot AvailableVentricular Repolarization1
1CompletedBasic SciencePain1
1CompletedOtherPain3
1CompletedPreventionPost-ERCP Acute Pancreatitis1
1CompletedSupportive CareHealthy Volunteers1
1CompletedTreatmentActinic Keratosis (AK)1
1CompletedTreatmentAdvanced Solid Tumors, Excluding Breast Cancer1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentInflammatory Reaction1
1CompletedTreatmentPain1
1RecruitingBasic ScienceAging1
1Unknown StatusBasic ScienceHealthy Volunteers1
1Unknown StatusTreatmentDiffuse Diabetic Macular Edema1
1, 2Unknown StatusTreatmentSuicidal Depression1
2CompletedHealth Services ResearchOsteoarthritis (OA)1
2CompletedPreventionNon-Melanomatous Skin Cancer1
2CompletedTreatmentAnkle Sprains1
2CompletedTreatmentBasal Cell Carcinoma (BCC)1
2CompletedTreatmentCutaneous Neurofibromas / Neurofibromatosis 11
2CompletedTreatmentHematuria / Lower Urinary Tract Symptoms (LUTS) / Pain1
2CompletedTreatmentIrreversible Pulpitis / Pain / Postoperative pain1
2CompletedTreatmentKnee Osteoarthritis (Knee OA)2
2CompletedTreatmentNon-steroidal Anti-inflammatory Poisoning1
2CompletedTreatmentOsteoarthritis (OA) / Wobenzym1
2CompletedTreatmentPain2
2CompletedTreatmentPerineal Laceration (Obstetric) / Perineal Tears1
2CompletedTreatmentPostoperative pain1
2CompletedTreatmentRheumatoid Arthritis1
2TerminatedTreatmentArthralgia / Kidney Failure,Chronic1
2TerminatedTreatmentOtitis Externa1
2WithdrawnTreatmentPlasma Cell Myeloma1
2, 3Active Not RecruitingPreventionIrreversible Pulpitis1
2, 3CompletedPreventionEndoscopy1
2, 3CompletedTreatmentBicipital Tendonitis / DeQuervain's Tenosynovitis of the Wrist / Lateral Epicondylitis of the Elbow / Medial Epicondylitis of the Elbow / Rotator Cuff Tendonitis / Subacromial Bursitis of the Shoulder / Subdeltoid Bursitis of the Shoulder1
2, 3RecruitingTreatmentDysmenorrhea1
2, 3RecruitingTreatmentPain, Acute1
2, 3TerminatedTreatmentAnkle Sprains1
2, 3TerminatedTreatmentBreast Pain / Non-cyclical Mastalgia / Surgical Scar-Related Breast Pain1
2, 3TerminatedTreatmentProphylaxis of Pulmonary embolism1
3Active Not RecruitingTreatmentActinic Keratosis (AK)1
3CompletedOtherActinic Keratosis (AK)1
3CompletedSupportive CareCoagulation Disorders / Knee Osteoarthritis (Knee OA)1
3CompletedSupportive CareMyopes Who Have Undergone PRK1
3CompletedTreatmentActinic Keratosis (AK)1
3CompletedTreatmentAcute Ankle Sprain1
3CompletedTreatmentAcute Blunt Soft Tissue Injuries/Contusions2
3CompletedTreatmentAcute Musculoskeletal Spasm Due to Low Back Pain1
3CompletedTreatmentAnaesthesia therapy1
3CompletedTreatmentAnkle Sprains2
3CompletedTreatmentAnkle Sprains / Pain, Acute1
3CompletedTreatmentAnkylosing Spondylitis (AS)2
3CompletedTreatmentArthroplasties Hip Replacement / Osteoarthritis, Hip / Perioperative Blood Loss1
3CompletedTreatmentElective Caesarean Section Surgeries1
3CompletedTreatmentGrade I/II Ankle Sprain1
3CompletedTreatmentKnee Osteoarthritis (Knee OA)4
3CompletedTreatmentMuscle Soreness1
3CompletedTreatmentOsteearthritis1
3CompletedTreatmentOsteoarthritis (OA)9
3CompletedTreatmentPain1
3CompletedTreatmentPain, Acute2
3CompletedTreatmentPain, Acute / Soft Tissue Injury1
3CompletedTreatmentPost Operative Dental Pain1
3CompletedTreatmentPostoperative pain4
3CompletedTreatmentRheumatoid Arthritis1
3CompletedTreatmentRheumatoid Arthritis,Osteoarthritis1
3CompletedTreatmentSprain of Ankle1
3CompletedTreatmentSunburn1
3CompletedTreatmentVertebrogenic Radiculopathy L5, S11
3Not Yet RecruitingPreventionPain, Procedure1
3Not Yet RecruitingTreatmentGraves Ophthalmopathy / Thyroid Associated Ophthalmopathy / Thyroid Associated Orbitopathy1
3Not Yet RecruitingTreatmentMechanical Low Back Pain / Postural Low Back Pain1
3RecruitingPreventionHysteroscopy / Pain1
3RecruitingPreventionPain1
3RecruitingPreventionPain, Post Procedural / Procedural Pain1
3RecruitingTreatmentInfertilities1
3RecruitingTreatmentKnee Osteoarthritis (Knee OA)2
3TerminatedTreatmentColic1
3TerminatedTreatmentGastric Ulcer (GU)1
3TerminatedTreatmentOsteoarthritis (OA)1
3TerminatedTreatmentPain1
3Unknown StatusPreventionBladder Cancers1
3Unknown StatusTreatmentKnee Injuries / Knee Pain Chronic1
3Unknown StatusTreatmentPostoperative pain1
4Active Not RecruitingTreatmentAthletic Injury1
4CompletedBasic ScienceActinic Keratosis (AK)1
4CompletedPreventionDisseminated Sclerosis1
4CompletedPreventionFamily Planning1
4CompletedPreventionGraves´ Disease1
4CompletedPreventionOsteoarthritis (OA) / Rheumatoid Arthritis1
4CompletedPreventionRecurrence of Febrile Seizure1
4CompletedScreeningDrug-Related Side Effects and Adverse Reactions1
4CompletedTreatmentAchilles Tendinopathy1
4CompletedTreatmentActinic Keratosis (AK)3
4CompletedTreatmentAcute Back Strain1
4CompletedTreatmentAcute Pseudophakic Cystoid Macular Edema1
4CompletedTreatmentAnkle Sprains1
4CompletedTreatmentCervical Pain1
4CompletedTreatmentCesarean Section1
4CompletedTreatmentDelayed Onset Muscle Soreness / Pain1
4CompletedTreatmentGlaucoma1
4CompletedTreatmentImpacted Third Molar Tooth1
4CompletedTreatmentInadequate or Impaired Respiratory Function / Pain1
4CompletedTreatmentIntraoperative Analgesic Use / Postcraniotomy Headache / Postoperative Analgesic Use / Postoperative Complications1
4CompletedTreatmentKnee Osteoarthritis (Knee OA)2
4CompletedTreatmentLow Back Pain (LBP)2
4CompletedTreatmentMigraines1
4CompletedTreatmentOrofacial Pain1
4CompletedTreatmentOsteoarthritis (OA)1
4CompletedTreatmentOsteoarthritis (OA) / Rheumatoid Arthritis1
4CompletedTreatmentOsteoarthritis, Hip1
4CompletedTreatmentPain2
4CompletedTreatmentPain / Sprains / Sprains and Strains1
4CompletedTreatmentParesthesia / Thoracic Pain1
4CompletedTreatmentPericardial Effusion1
4CompletedTreatmentPharyngitis1
4CompletedTreatmentPhotosensitivity Disorders1
4CompletedTreatmentPostoperative pain1
4CompletedTreatmentPrimary Dysmenorrhoea1
4CompletedTreatmentRenal Colic / Urinary Calculi1
4CompletedTreatmentSuperficial Thrombophlebitis of the Upper Limb1
4RecruitingDiagnosticFemale Infertility of Tubal Origin1
4RecruitingPreventionAnaesthesia therapy / Hip Fractures1
4RecruitingPreventionCesarean Delivery1
4RecruitingTreatmentMigrainous Headache1
4TerminatedPreventionPancreatitis1
4TerminatedTreatmentAnkylosing Spondylitis (AS) / Pain1
4TerminatedTreatmentFevers1
4TerminatedTreatmentPain2
4TerminatedTreatmentUrinary Tract Infections (UTIs)1
4Unknown StatusTreatmentRheumatoid Arthritis1
4Unknown StatusTreatmentSubarachnoid Hemorrhage / Traumatic Brain Injury (TBI)1
4WithdrawnTreatmentHallux Valgus / Postoperative pain1
4WithdrawnTreatmentSprains1
4WithdrawnTreatmentUpper Respiratory Tract Infections1
Not AvailableApproved for MarketingNot AvailableOsteoarthritis of the Hands1
Not AvailableCompletedNot AvailableActinic Keratosis (AK)1
Not AvailableCompletedNot AvailableBMI >27 kg/m2 / BMI >30 kg/m2 / Inflammatory Reaction1
Not AvailableCompletedNot AvailableComplex Regional Pain Syndrome (CRPS) / Complex Regional Pain Syndrome Type I / Neurocostal neuralgia / Postherpetic Neuralgia1
Not AvailableCompletedBasic ScienceAnterior Uveitis (AU) / Iridocyclitis / Iritis / Macular Edema (ME) / Uveitis1
Not AvailableCompletedBasic ScienceLow Back Pain (LBP)1
Not AvailableCompletedBasic SciencePhysiological Conditions1
Not AvailableCompletedDiagnosticDermatitis, Photocontact1
Not AvailableCompletedPreventionCataracts / Macular Edema (ME) / Retinopathy, Diabetic1
Not AvailableCompletedPreventionPain1
Not AvailableCompletedPreventionRetinopathy, Diabetic1
Not AvailableCompletedSupportive CarePain1
Not AvailableCompletedTreatmentDysmenorrhea / Electromagnetic Field1
Not AvailableCompletedTreatmentFevers / Reduction in Temperature1
Not AvailableCompletedTreatmentHealthy Volunteers1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)2
Not AvailableCompletedTreatmentOsteoarthritis of the Knee Joint1
Not AvailableCompletedTreatmentPost Cesarean Pain Management1
Not AvailableCompletedTreatmentPostoperative pain1
Not AvailableCompletedTreatmentSpinal Stenosis of Lumbar Region1
Not AvailableEnrolling by InvitationNot AvailableArthritis / Gout Acute / Headaches / Migraines / Muscle Spasms / Radicular syndrome / Synovitis / Tendonitis1
Not AvailableNot Yet RecruitingNot AvailableDisorders, Blood Coagulation1
Not AvailableRecruitingNot AvailableInflamation Management / Pain Management / Post Surgical Management1
Not AvailableRecruitingPreventionNon-Melanoma Skin Cancer (NMSC)1
Not AvailableRecruitingPreventionNulliparity1
Not AvailableRecruitingTreatmentGeneral Surgery / Pain / Rib Fractures / Traumas1
Not AvailableRecruitingTreatmentImpacted Third Molar Tooth1
Not AvailableRecruitingTreatmentRhizarthrosis1
Not AvailableUnknown StatusBasic ScienceSupersaturation and Precipitation in the Stomach1
Not AvailableUnknown StatusPreventionPost ERCP Pancreatitis1
Not AvailableUnknown StatusTreatmentAbnormal Uterine Bleeding Unrelated to Menstrual Cycle1
Not AvailableUnknown StatusTreatmentFlail Chest / General Surgery / Rib Fractures / Traumas1
Not AvailableUnknown StatusTreatmentPain Relief1
Not AvailableUnknown StatusTreatmentSciatica Due to Intervertebral Disc Disorder1
Not AvailableWithdrawnTreatmentAnkle Sprains / Pain1
Not AvailableWithdrawnTreatmentPostoperative pain1

Pharmacoeconomics

Manufacturers
  • Institut biochemique sa
  • Xanodyne pharmaceutics inc
  • Nautilus neurosciences inc
  • Novartis pharmaceuticals corp
  • Apotex inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Nycomed us inc
  • Novartis consumer health inc
  • Akorn inc
  • Alcon inc
  • Apotex inc richmond hill
  • Bausch and lomb inc
  • Falcon pharmaceuticals ltd
  • Nexus pharmaceuticals inc
  • Mallinckrodt inc
  • Actavis elizabeth llc
  • Alphapharm party ltd
  • Carlsbad technology inc
  • Nostrum laboratories inc
  • Pliva inc
  • Roxane laboratories inc
  • Teva pharmaceuticals usa
  • Unique pharmaceutical laboratories
  • Biovail laboratories inc
  • Dexcel ltd
Packagers
Dosage forms
FormRouteStrength
Tablet, delayed releaseOral25 mg
Tablet, delayed releaseOral50 mg
Tablet, extended releaseOral100 mg
SolutionOphthalmic0.1 %
Tablet, film coatedOral
Powder, for solutionOral1 mg/mg
Powder, for solutionOral50 mg/1
Powder, for solutionOral50 mg
Tablet, sugar coatedOral50 mg/1
TabletOral50 mg/1
Tablet, film coatedOral50 mg/1
PowderOral50 mg/1
Aerosol, meteredTopical30 mg/mL
GelTopical10 mg/1
GelTopical3 g/100g
GelTopical30 mg/g
SolutionOphthalmic1 mg/mL
SolutionTopical16.05 mg/mL
Solution / dropsOphthalmic1 mg/mL
Solution / dropsOphthalmic3.5 mg/mL
Solution / dropsTransdermal16.05 mg/mL
Tablet, delayed releaseOral25 mg/1
CreamTopical300 mg/g
Tablet, delayed releaseOral
Tablet, delayed releaseOral50 mg/1
Tablet, delayed releaseOral75 mg/1
Tablet, extended releaseOral100 mg/1
GelTopical1 g/1
Injection, solutionIntravenous37.5 mg/mL
PatchTopical180 mg/1
PatchTopical180 mg/14g
KitTopical
Kit
LiquidTopical16.05 mg/mL
SolutionTopical1.5 %
SolutionTopical20 mg/g
SuppositoryRectal100 mg
SuppositoryRectal50 mg
Kit
TabletOral
TabletOral25 mg
Tablet, extended releaseOral75 mg
CreamTopical
LiquidOphthalmic0.1 %
GelTopical10 mg/g
GelTopical1.16 %
GelTopical2.32 %
TabletOral50 mg
Tablet, film coated, extended releaseOral100 mg/1
Capsule, liquid filledOral25 mg/1
CapsuleOral18 mg/1
CapsuleOral35 mg/1
Prices
Unit descriptionCostUnit
Voltaren Ophtha 0.1 % Solution2.73USD ml
Voltaren 100 mg Suppository1.88USD suppository
Voltaren Sr 100 mg Sustained-Release Tablet1.86USD tablet
Voltaren 50 mg Suppository1.4USD suppository
Voltaren Sr 75 mg Sustained-Release Tablet1.31USD tablet
Voltaren 50 mg Enteric-Coated Tablet0.93USD tablet
Pms-Diclofenac 100 mg Suppository0.88USD suppository
Sandoz Diclofenac 100 mg Suppository0.88USD suppository
Novo-Difenac Sr 100 mg Sustained-Release Tablet0.8USD tablet
Pms-Diclofenac-Sr 100 mg Sustained-Release Tablet0.8USD tablet
Sandoz Diclofenac Sr 100 mg Sustained-Release Tablet0.8USD tablet
Pms-Diclofenac 50 mg Suppository0.65USD suppository
Sandoz Diclofenac 50 mg Suppository0.65USD suppository
Novo-Difenac Sr 75 mg Sustained-Release Tablet0.6USD tablet
Pms-Diclofenac-Sr 75 mg Sustained-Release Tablet0.6USD tablet
Sandoz Diclofenac Sr 75 mg Sustained-Release Tablet0.6USD tablet
Apo-Diclo 50 mg Enteric-Coated Tablet0.4USD tablet
Novo-Difenac 50 mg Enteric-Coated Tablet0.4USD tablet
Pms-Diclofenac 50 mg Enteric-Coated Tablet0.4USD tablet
Sandoz Diclofenac 50 mg Enteric-Coated Tablet0.4USD tablet
Apo-Diclo 25 mg Enteric-Coated Tablet0.2USD tablet
Novo-Difenac 25 mg Enteric-Coated Tablet0.2USD tablet
Nu-Diclo 25 mg Enteric-Coated Tablet0.2USD tablet
Pms-Diclofenac 25 mg Enteric-Coated Tablet0.2USD tablet
Sandoz Diclofenac 25 mg Enteric-Coated Tablet0.2USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6407079No1999-06-182019-06-18Us
US8217078No2009-07-102029-07-10Us
US8546450No2010-08-092030-08-09Us
US8618164No2009-07-102029-07-10Us
US8741956No2009-07-102029-07-10Us
US5985850No1995-08-112015-08-11Us
US5792753No1995-08-112015-08-11Us
US5914322No1995-08-112015-08-11Us
US5607690No1999-04-132019-04-13Us
US6974595No1997-05-152017-05-15Us
US7482377No1997-05-152017-05-15Us
US7759394No2006-06-162026-06-16Us
US8097651No2006-06-162026-06-16Us
US8927604No2006-06-162026-06-16Us
US6365180No1999-07-152019-07-15Us
US7662858No2009-02-242029-02-24Us
US7884095No2009-02-242029-02-24Us
US7939518No2009-02-242029-02-24Us
US8110606No2009-02-242029-02-24Us
US8623920No2009-02-242029-02-24Us
US6287594No1999-01-152019-01-15Us
US8946292No2007-03-222027-03-22Us
US9180095No2010-04-232030-04-23Us
US9186328No2010-04-232030-04-23Us
US8999387No2010-04-232030-04-23Us
US9173854No2010-04-232030-04-23Us
US9180096No2010-04-232030-04-23Us
US9017721No2010-04-232030-04-23Us
US8679544No2010-04-232030-04-23Us
US8252838No2008-04-212028-04-21Us
US8563613No2007-10-172027-10-17Us
US8871809No2007-10-172027-10-17Us
US9132110No2007-10-172027-10-17Us
US9220784No2007-10-172027-10-17Us
US9101591No2007-10-172027-10-17Us
US9168305No2007-10-172027-10-17Us
US9066913No2007-10-172027-10-17Us
US9168304No2007-10-172027-10-17Us
US9561200No2009-02-242029-02-24Us
US9370501No2009-07-102029-07-10Us
US9375412No2009-07-102029-07-10Us
US9339552No2007-10-172027-10-17Us
US9539335No2007-10-172027-10-17Us
US9415029No2009-07-102029-07-10Us
US9339551No2007-10-172027-10-17Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)283-285 °CNot Available
water solubility2.37 mg/L (at 25 °C)FINI,A ET AL. (1986)
logP4.51AVDEEF,A (1997)
pKa4.15SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00447 mg/mLALOGPS
logP4.98ALOGPS
logP4.26ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)4ChemAxon
pKa (Strongest Basic)-2.1ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity75.46 m3·mol-1ChemAxon
Polarizability27.93 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9548
Blood Brain Barrier+0.9541
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.7976
P-glycoprotein inhibitor INon-inhibitor0.8254
P-glycoprotein inhibitor IINon-inhibitor0.9548
Renal organic cation transporterNon-inhibitor0.9086
CYP450 2C9 substrateNon-substrate0.7779
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6724
CYP450 1A2 substrateInhibitor0.5923
CYP450 2C9 inhibitorInhibitor0.6786
CYP450 2D6 inhibitorNon-inhibitor0.848
CYP450 2C19 inhibitorNon-inhibitor0.8947
CYP450 3A4 inhibitorNon-inhibitor0.8647
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6607
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.6706
BiodegradationNot ready biodegradable0.9719
Rat acute toxicity3.6447 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9514
hERG inhibition (predictor II)Non-inhibitor0.868
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-03xv-3390000000-cd724f772f8ff3648856
Mass Spectrum (Electron Ionization)MSsplash10-03xv-1290000000-8fb3ce6f68fc69b5218e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0090000000-1d8a04523a99bbdd0f79
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0090000000-55cf6c5663edc2bce2af
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0090000000-0257da659c18c3020ebe
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0w29-0090000000-eba79744370d30689f45
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03fr-0890000000-0870dbb742038ce60ba1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0900000000-a9b9817f70b72a327169
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0090000000-58aba74cf5c165b0b3e5
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0090000000-380ce6ec03fa880c2fee
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0w29-0090000000-1c764b23643b9731a5a2
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0ik9-0290000000-5d59b6e5d4465a9e6493
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0900000000-483b1ac79bbfb8f591c2
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0fb9-0950000000-4192d5344ed223d4bfd6
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0090000000-1d8a04523a99bbdd0f79
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0006-0090000000-d28bb6688b1bce51bfce
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0udi-0090000000-33332a8dbce37d5ad759
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0udi-1490000000-f1c9ca0a1b924dba188e
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-004i-4910000000-4c58f3f969da3d86e23c
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00or-7900000000-3b2e03ec45a0b642cb4d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0390000000-247401e4df8c88d9f260
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0f6t-0980000000-dee808683174f31bbd7b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0090000000-5685aad1c834522ac60a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0090000000-5685aad1c834522ac60a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0090000000-659ebbc59b4a39d35b04
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udj-0090000000-f5310eb88501c49fae99
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0090000000-22b25c07db224512f663
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0090000000-185b3e61f8dee1cd34fd
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-258397c7de133a923918
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0190000000-a01fa70dc6bb2e228326
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0090000000-dda6bd4971ef03dfabd5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f92-0090000000-2442038174fa86b3208e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-6651d739e4ae3414e4dc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-d36dd717311d2b0886bd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0090000000-ce3de7d00b24b610d60e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0090000000-79f23644751784fec0ff
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0090000000-2b7106a8023f21da905f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f92-0090000000-3a985a8972fed8e003bb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-97ab164f74166b6b9013
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-0e7b515022ec37b87106
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0090000000-4bc6d8a15c3425f5cd10
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0090000000-80bb26643a94999c6114
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0090000000-e5473cba8c9d7b59691b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0090000000-f4f62ca3d4d5ab12ba13
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-002b-0190000000-5072b5cbb937155d3784
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0fr2-0690000000-0ad1d80cd74eb2ccbdb0
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014j-0690000000-4183a2580dc0b109b758
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03dj-1590000000-fbe48d026f4e8bbc143f
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03di-2590000000-f9746f93eefd2c1420c4
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0fb9-0090000000-ea3b07d4dee166a8e13a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03xr-0090000000-e46d3368f4461372a4d3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0090000000-6f11e14bc0fc7b731ddb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0090000000-c297b571605fec05d894
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0090000000-044f51839f5d4002b30d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0i00-0090000000-c627af8df018c1c51b07

Taxonomy

Description
This compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Dichlorobenzenes
Alternative Parents
Aniline and substituted anilines / Aryl chlorides / Amino acids / Secondary amines / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Aniline or substituted anilines / 1,3-dichlorobenzene / Aryl chloride / Aryl halide / Amino acid or derivatives / Amino acid / Carboxylic acid derivative / Carboxylic acid / Secondary amine / Monocarboxylic acid or derivatives
show 12 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monocarboxylic acid, secondary amino compound, dichlorobenzene, aromatic amine, amino acid (CHEBI:47381)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J: Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol. 2003 Jan;55(1):51-61. [PubMed:12534640]
  2. Blomme EA, Chinn KS, Hardy MM, Casler JJ, Kim SH, Opsahl AC, Hall WA, Trajkovic D, Khan KN, Tripp CS: Selective cyclooxygenase-2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. Br J Dermatol. 2003 Feb;148(2):211-23. [PubMed:12588370]
  3. Beubler E: [Pharmacology of cyclooxygenase 2 inhibition]. Wien Med Wochenschr. 2003;153(5-6):95-9. [PubMed:12705061]
  4. Chavez ML, DeKorte CJ: Valdecoxib: a review. Clin Ther. 2003 Mar;25(3):817-51. [PubMed:12852704]
  5. Rowlinson SW, Kiefer JR, Prusakiewicz JJ, Pawlitz JL, Kozak KR, Kalgutkar AS, Stallings WC, Kurumbail RG, Marnett LJ: A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem. 2003 Nov 14;278(46):45763-9. Epub 2003 Aug 18. [PubMed:12925531]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Calkin AC, Sudhir K, Honisett S, Williams MR, Dawood T, Komesaroff PA: Rapid potentiation of endothelium-dependent vasodilation by estradiol in postmenopausal women is mediated via cyclooxygenase 2. J Clin Endocrinol Metab. 2002 Nov;87(11):5072-5. [PubMed:12414874]
  2. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J: Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol. 2003 Jan;55(1):51-61. [PubMed:12534640]
  3. Kampfer H, Brautigam L, Geisslinger G, Pfeilschifter J, Frank S: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. J Invest Dermatol. 2003 May;120(5):880-90. [PubMed:12713596]
  4. Chavez ML, DeKorte CJ: Valdecoxib: a review. Clin Ther. 2003 Mar;25(3):817-51. [PubMed:12852704]
  5. Hinz B, Rau T, Auge D, Werner U, Ramer R, Rietbrock S, Brune K: Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35. [PubMed:12966366]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Iron ion binding
Specific Function
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name
ALOX5
Uniprot ID
P09917
Uniprot Name
Arachidonate 5-lipoxygenase
Molecular Weight
77982.595 Da
References
  1. Charlier C, Michaux C: Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur J Med Chem. 2003 Jul-Aug;38(7-8):645-59. [PubMed:12932896]
  2. Kudo C, Kori M, Matsuzaki K, Yamai K, Nakajima A, Shibuya A, Niwa H, Kamisaki Y, Wada K: Diclofenac inhibits proliferation and differentiation of neural stem cells. Biochem Pharmacol. 2003 Jul 15;66(2):289-95. [PubMed:12826271]
  3. Whittle BJ: Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer anti-inflammatory drugs. Curr Opin Pharmacol. 2004 Dec;4(6):538-45. [PubMed:15525540]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN4A
Uniprot ID
P35499
Uniprot Name
Sodium channel protein type 4 subunit alpha
Molecular Weight
208059.175 Da
References
  1. Yang YC, Kuo CC: An inactivation stabilizer of the Na+ channel acts as an opportunistic pore blocker modulated by external Na+. J Gen Physiol. 2005 May;125(5):465-81. Epub 2005 Apr 11. [PubMed:15824190]
  2. Voilley N: Acid-sensing ion channels (ASICs): new targets for the analgesic effects of non-steroid anti-inflammatory drugs (NSAIDs). Curr Drug Targets Inflamm Allergy. 2004 Mar;3(1):71-9. [PubMed:15032643]
  3. Jones NG, Slater R, Cadiou H, McNaughton P, McMahon SB: Acid-induced pain and its modulation in humans. J Neurosci. 2004 Dec 1;24(48):10974-9. [PubMed:15574747]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ligand-gated sodium channel activity
Specific Function
Isoform 2 and isoform 3 function as proton-gated sodium channels; they are activated by a drop of the extracellular pH and then become rapidly desensitized. The channel generates a biphasic current...
Gene Name
ASIC1
Uniprot ID
P78348
Uniprot Name
Acid-sensing ion channel 1
Molecular Weight
59908.915 Da
References
  1. Voilley N, de Weille J, Mamet J, Lazdunski M: Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors. J Neurosci. 2001 Oct 15;21(20):8026-33. [PubMed:11588175]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Other
General Function
Voltage-gated potassium channel activity
Specific Function
Probably important in the regulation of neuronal excitability. Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current...
Gene Name
KCNQ2
Uniprot ID
O43526
Uniprot Name
Potassium voltage-gated channel subfamily KQT member 2
Molecular Weight
95846.575 Da
References
  1. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972]
  2. Xiong Q, Gao Z, Wang W, Li M: Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds. Trends Pharmacol Sci. 2008 Feb;29(2):99-107. doi: 10.1016/j.tips.2007.11.010. Epub 2008 Jan 18. [PubMed:18206251]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Other
General Function
Voltage-gated potassium channel activity
Specific Function
Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native ...
Gene Name
KCNQ3
Uniprot ID
O43525
Uniprot Name
Potassium voltage-gated channel subfamily KQT member 3
Molecular Weight
96741.515 Da
References
  1. Xiong Q, Gao Z, Wang W, Li M: Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds. Trends Pharmacol Sci. 2008 Feb;29(2):99-107. doi: 10.1016/j.tips.2007.11.010. Epub 2008 Jan 18. [PubMed:18206251]
  2. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Phospholipid binding
Specific Function
Thought to participate in the regulation of the phospholipid metabolism in biomembranes including eicosanoid biosynthesis. Catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-ph...
Gene Name
PLA2G2A
Uniprot ID
P14555
Uniprot Name
Phospholipase A2, membrane associated
Molecular Weight
16082.525 Da
References
  1. Madanick RD, O'Loughlin CJ, Barkin JS: Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Dig Dis Sci. 2005 May;50(5):879-81. [PubMed:15906762]
  2. Singh N, Jabeen T, Sharma S, Somvanshi RK, Dey S, Srinivasan A, Singh TP: Specific binding of non-steroidal anti-inflammatory drugs (NSAIDs) to phospholipase A2: structure of the complex formed between phospholipase A2 and diclofenac at 2.7 A resolution. Acta Crystallogr D Biol Crystallogr. 2006 Apr;62(Pt 4):410-6. Epub 2006 Mar 18. [PubMed:16552142]
  3. Makela A, Kuusi T, Schroder T: Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest. 1997 Aug;57(5):401-7. [PubMed:9279965]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF: New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126. [PubMed:20167001]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Obach RS, Reed-Hagen AE: Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos. 2002 Jul;30(7):831-7. [PubMed:12065442]
  5. Leemann T, Transon C, Dayer P: Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sci. 1993;52(1):29-34. [PubMed:8417277]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Details
8. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C18
Uniprot ID
P33260
Uniprot Name
Cytochrome P450 2C18
Molecular Weight
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Identical protein binding
Specific Function
Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.
Gene Name
TTR
Uniprot ID
P02766
Uniprot Name
Transthyretin
Molecular Weight
15886.88 Da
References
  1. Miller SR, Sekijima Y, Kelly JW: Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest. 2004 May;84(5):545-52. [PubMed:14968122]
  2. Almeida MR, Macedo B, Cardoso I, Alves I, Valencia G, Arsequell G, Planas A, Saraiva MJ: Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem J. 2004 Jul 15;381(Pt 2):351-6. [PubMed:15080795]
Details
2. Serum albumin
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Yamasaki K, Rahman MH, Tsutsumi Y, Maruyama T, Ahmed S, Kragh-Hansen U, Otagiri M: Circular dichroism simulation shows a site-II-to-site-I displacement of human serum albumin-bound diclofenac by ibuprofen. AAPS PharmSciTech. 2000 May 14;1(2):E12. [PubMed:14727845]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603. [PubMed:11743742]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]
  2. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528]
  3. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Thyroid hormone transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-gluc...
Gene Name
SLCO1C1
Uniprot ID
Q9NYB5
Uniprot Name
Solute carrier organic anion transporter family member 1C1
Molecular Weight
78695.625 Da
References
  1. Westholm DE, Stenehjem DD, Rumbley JN, Drewes LR, Anderson GW: Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. Endocrinology. 2009 Feb;150(2):1025-32. doi: 10.1210/en.2008-0188. Epub 2008 Oct 9. [PubMed:18845642]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18